CoChat

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

Mulder, André B., van Lijf, Hans J., Bon, Michelle A. M., van den Bergh, Frank A. J. T. M., Touw, Daan J., Neef, Cees, Vermes, István · 2001 · Clinical Pharmacology & Therapeutics
Cited by 136

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective: Because clinical data about the therapeutic consequences of polymorphic oxidation of simvastatin by CYP2D6 have not been well reported, we sought to investigate the possible link between polymorphism of CYP2D6 and the efficacy and tolerability of simvastatin treatment in a group of 88 patients with hypercholesterolemia. Methods: The CYP2D6 genotype was determined with use of polymerase chain reaction and restriction fragment analysis, whereas the CYP2D6 phenotype was determined by monitoring the dextromethorphan metabolism. Results: Four of 5 patients with 2 defective CYP2D6 alleles discontinued the therapy at a low daily dose because of adverse events, with a significant mean decrease in the cholesterol levels of 0.23 mmol/L per milligram of simvastatin in the daily dose. In the group of 28 patients with 1 mutated CYP2D6 gene, 13 did not tolerate the therapy, whereas a mean decrease in the cholesterol levels of 0.20 mmol/L per milligram of simvastatin was found. One patient with a multiplication of the CYP2D6 gene showed a cholesterol reduction of only 0.01 mmol/L per milligram of simvastatin, at a maximal daily dose of 40 mg. Only 9 patients of the group of 54 persons who were homozygous for the wild‐type allele discontinued the therapy because of intolerance. In that group, a mean decrease of cholesterol of 0.10 mmol/L per milligram of simvastatin was observed. Conclusions: Our data provide evidence that the cholesterol‐lowering effect of simvastatin is influenced by CYP2D6 polymorphism. The clinical use of this knowledge may allow for more efficient individual therapies. Clinical Pharmacology & Therapeutics (2001) 70, 546–551; doi: 10.1016/S0009‐9236(01)25429‐0

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0009-9236(01)25429-0

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 136

Metadata

Authors
Mulder, A. B., van Lijf, H. J., Bon, M. A. M., van den Bergh, F. A. J. T. M., Touw, D. J., Neef, C., & Vermes, I.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2001-12
Volume
70
Issue
6
Pages
546-551
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2110359256
Cited by
136
References
1
FWCI
5.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. https://app.cochat.ai/papers/10.1016/s0009-9236(01)25429-0
The paper
Mulder, A. B., van Lijf, H. J., Bon, M. A. M., van den Bergh, F. A. J. T. M., Touw, D. J., Neef, C., & Vermes, I. (2001). Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(01)25429-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.